The Nutshell

» cancer and disease/medicine

Daily News Roundup

Most Recent

image: Papers Based on Misidentified Cell Lines Top 32,000

Papers Based on Misidentified Cell Lines Top 32,000

By | October 16, 2017

An analysis of contaminated literature finds that tens of thousands of papers used cell lines of questionable origins—and these were in turn cited by hundreds of thousands of other papers.

1 Comment

Spark Therapeutics’s Luxturna would be the first approved therapy in the U.S. that replaces or repairs a defective gene inherited from one’s parents.

3 Comments

image: Study Raises Questions About Patient-Derived Xenografts

Study Raises Questions About Patient-Derived Xenografts

By | October 10, 2017

When transplanted into mice, tumor genomes evolve differently than they do in patients, study finds.

1 Comment

Tissue recipients were treated as “guinea pigs,” says investigation leader.

0 Comments

Researchers use base-editing to swap out an erroneous nucleotide responsible for a potentially life-threatening blood disorder.

0 Comments

image: Enormous University Gift Raises Questions over Donor Influence

Enormous University Gift Raises Questions over Donor Influence

By | September 26, 2017

The donation to the University of California, Irvine, is slated to fund a new college focusing on what some critics call pseudoscience and quackery.

9 Comments

image: Study: Alcohol Industry Distorts Cancer Risk

Study: Alcohol Industry Distorts Cancer Risk

By | September 10, 2017

Researchers claim that industry groups worldwide misrepresent the carcinogenicity of alcohol products.

0 Comments

image: How Exercise Might Fight Cancer

How Exercise Might Fight Cancer

By | September 8, 2017

Epinephrine’s activation of the signaling pathway Hippo is responsible for the in vitro tumor-fighting effects of serum from women who worked out.

0 Comments

Douglas Lowy and John Schiller, whose work led to the HPV vaccine, and Michael Hall, who discovered the TOR pathway, win this year’s prizes.

0 Comments

image: Gilead to Pay Nearly $12B for CAR T-Cell Company

Gilead to Pay Nearly $12B for CAR T-Cell Company

By | August 28, 2017

The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.

0 Comments

Popular Now

  1. Man Receives First In Vivo Gene-Editing Therapy
  2. Researchers Build a Cancer Immunotherapy Without Immune Cells
  3. Immune Checkpoint Found Lacking in Type 1 Diabetes
  4. Research Links Gut Health to Neurodegeneration
    The Nutshell Research Links Gut Health to Neurodegeneration

    Rodent studies presented at the Society for Neuroscience meeting this week tie pathologies in the gastrointestinal tract or microbiome composition with Parkinson’s and Alzheimer’s diseases.

RayBiotech